Insider Selling: ANI Pharmaceuticals (NASDAQ:ANIP) Director Sells 2,000 Shares of Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Director Thomas Haughey sold 2,000 shares of the stock in a transaction dated Monday, June 8th. The shares were sold at an average price of $80.88, for a total value of $161,760.00. Following the completion of the transaction, the director directly owned 38,878 shares of the company’s stock, valued at $3,144,452.64. This represents a 4.89% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

ANI Pharmaceuticals Stock Up 0.8%

ANIP traded up $0.65 on Wednesday, reaching $81.85. The company’s stock had a trading volume of 268,475 shares, compared to its average volume of 313,632. The stock has a market cap of $1.86 billion, a price-to-earnings ratio of 20.72 and a beta of 0.44. ANI Pharmaceuticals, Inc. has a 1 year low of $61.17 and a 1 year high of $99.50. The company has a debt-to-equity ratio of 1.06, a current ratio of 3.12 and a quick ratio of 2.52. The business’s 50 day moving average is $79.51 and its 200 day moving average is $79.39.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its quarterly earnings results on Friday, May 8th. The specialty pharmaceutical company reported $2.05 EPS for the quarter, beating analysts’ consensus estimates of $1.28 by $0.77. The firm had revenue of $237.46 million during the quarter, compared to the consensus estimate of $207.63 million. ANI Pharmaceuticals had a return on equity of 27.51% and a net margin of 9.98%.ANI Pharmaceuticals’s revenue for the quarter was up 20.5% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.70 earnings per share. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. As a group, research analysts forecast that ANI Pharmaceuticals, Inc. will post 8.07 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts recently commented on ANIP shares. Weiss Ratings reissued a “hold (c+)” rating on shares of ANI Pharmaceuticals in a report on Monday, June 1st. Zacks Research downgraded ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 14th. Finally, Wall Street Zen upgraded ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 9th. Five investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $107.33.

Institutional Trading of ANI Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Bank of America Corp DE raised its position in shares of ANI Pharmaceuticals by 229.4% during the 1st quarter. Bank of America Corp DE now owns 150,532 shares of the specialty pharmaceutical company’s stock worth $11,576,000 after purchasing an additional 104,828 shares during the period. Janus Henderson Group PLC raised its position in shares of ANI Pharmaceuticals by 1,308.1% during the 1st quarter. Janus Henderson Group PLC now owns 109,552 shares of the specialty pharmaceutical company’s stock worth $8,425,000 after purchasing an additional 101,772 shares during the period. California State Teachers Retirement System raised its position in shares of ANI Pharmaceuticals by 57.3% during the 1st quarter. California State Teachers Retirement System now owns 24,557 shares of the specialty pharmaceutical company’s stock worth $1,888,000 after purchasing an additional 8,946 shares during the period. The Manufacturers Life Insurance Company raised its position in shares of ANI Pharmaceuticals by 1.5% during the 1st quarter. The Manufacturers Life Insurance Company now owns 9,577 shares of the specialty pharmaceutical company’s stock worth $736,000 after purchasing an additional 143 shares during the period. Finally, Quantinno Capital Management LP raised its position in shares of ANI Pharmaceuticals by 345.4% during the 1st quarter. Quantinno Capital Management LP now owns 15,167 shares of the specialty pharmaceutical company’s stock worth $1,166,000 after purchasing an additional 11,762 shares during the period. 76.05% of the stock is currently owned by institutional investors and hedge funds.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.